ID 11918
Alternative Names: ID 11918Latest Information Update: 28 Feb 2025
At a glance
- Originator Ildong Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for research development in Prostate-cancer(Hormone refractory) in South Korea
- 25 Jan 2021 Early research in Prostate cancer (Hormone refractory) in South Korea (unspecified route) (Ildong Pharmaceutical pipeline January 2021)